22157.jpg
Outlook on the Nuclear Medicine Global Market to 2028: Use of Radiopharmaceuticals in Neurological Applications Presents Opportunities
16 nov. 2022 04h08 HE | Research and Markets
Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's...
POINT logo light blue (png).png
POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings
14 nov. 2022 07h15 HE | POINT Biopharma
INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT logo light blue (png).png
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
14 nov. 2022 07h00 HE | POINT Biopharma
Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticalsExpands Lantheus’ portfolio...
ITM_Logo_Claim_RGB_high-res.png
ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)
27 oct. 2022 05h00 HE | ITM Isotope Technologies Munich SE
Garching / Munich, October 27, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has...
LOGO.jpg
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
26 oct. 2022 08h00 HE | QSAM Biosciences Inc.
Austin, TX, Oct. 26, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
22157.jpg
Outlook on the Radiotheranostics Global Market to 2027 - Regulatory Approval of Numerous Radiotheranostics Pairs is Expected to Boost Their Adoption for Cancer Treatments
25 oct. 2022 08h18 HE | Research and Markets
Dublin, Oct. 25, 2022 (GLOBE NEWSWIRE) -- The "Global Radiotheranostics Market by Radioisotope, Application, End-user and Region: Competition Forecast and Opportunities to 2027" report has been...
POINT-Logo-Colour (blue).png
POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANM’s Annual Congress
17 oct. 2022 08h30 HE | POINT Biopharma
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA...
ITM_Logo_Claim_RGB_high-res.png
ITM Multiplies Production Capacity for its n.c.a. Lutetium-177
13 oct. 2022 05h00 HE | ITM Isotope Technologies Munich SE
Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production...
22157.jpg
Outlook on the Nuclear Medicine Equipment Global Market to 2030 - Rising Adoption of Nuclear Medicine Equipment and Emergence of Innovative & Advanced Equipment is Driving Growth
07 oct. 2022 07h53 HE | Research and Markets
Dublin, Oct. 07, 2022 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Equipment Market By Product, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has...
POINT-Logo-Colour (blue).png
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
16 sept. 2022 16h30 HE | POINT Biopharma
INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...